Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?

被引：0
|
作者：
Kadri Altundag
机构：
[1] MKA Breast Cancer Clinic,
来源：
Journal of Neuro-Oncology | 2017年 / 135卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：639 / 639
相关论文
共 50 条
  • [21] HER2 status of circulating tumor cells in HER2-positive metastatic breast cancer patients: A valuable biomarker in anti-HER2 therapy
    Jiang, Z.
    Li, L.
    Liu, Y.
    Wang, T.
    Zhang, S.
    Yuan, Y.
    Bian, L.
    Liu, Q.
    Qi, F.
    CANCER RESEARCH, 2013, 73
  • [22] Decreased HER2 expression in endometrial cancer following anti-HER2 therapy
    Chui, M. Herman
    Brown, David N.
    Paula, Arnaud Da Cruz
    da Silva, Edaise M.
    Momeni-Boroujeni, Amir
    Reis-Filho, Jorge S.
    Zhang, Yanming
    Makker, Vicky
    Ellenson, Lora Hedrick
    Weigelt, Britta
    JOURNAL OF PATHOLOGY, 2024, 262 (02): : 129 - 136
  • [23] 131I-Labeled Anti-HER2 Nanobody for Targeted Radionuclide Therapy of HER2-Positive Breast Cancer
    Zhao, Lingzhou
    Gong, Jiali
    Qi, Qinli
    Liu, Changcun
    Su, Hongxing
    Xing, Yan
    Zhao, Jinhua
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2023, 18 : 1915 - 1925
  • [24] Alternative targeted therapy for early Her2 positive breast cancer
    Harvey, Sandra L.
    Khasraw, Mustafa
    GLAND SURGERY, 2013, 2 (01) : 42 - 45
  • [25] Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
    Xie, Yifan
    Wu, Siyu
    Zhang, Ying
    Li, Jianwei
    Mo, Miao
    Shao, Zhimin
    Liu, Guangyu
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] Quantitative diagnostic technology for HER2 positive breast cancer by molecular imaging: The potential predictive factor of anti-HER2 therapy
    Miyashita, M.
    Gonda, K.
    Tada, H.
    Watanabe, M.
    Ishida, T.
    Sasano, H.
    Ohuchi, N.
    CANCER RESEARCH, 2013, 73
  • [27] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy.
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    MODERN PATHOLOGY, 2018, 31 : 91 - 91
  • [28] HER2 Low-Amplified Breast Cancer: The Efficacy of Anti-HER2 Therapy in Neoadjuvant Setting
    Lv, Hong
    Bai, Qianming
    Shui, Ruohong
    Xu, Xiaoli
    Yu, Bao-Hua
    Bi, Rui
    Cheng, Yufan
    Tu, Xiaoyu
    Zhou, Xiaoyan
    Yang, Wentao
    LABORATORY INVESTIGATION, 2023, 103 (03) : S177 - S178
  • [29] Non-HER2 patients might still be targeted for anti-HER2 therapy Somatic HER2 mutations identified as targets for breast cancer treatment
    Wilson, Hannah
    BREAST CANCER MANAGEMENT, 2013, 2 (02) : 94 - 95
  • [30] Anti-HER2 therapy for HER2-positive metastatic breast cancer: regimens and treatment outcomes
    Watanabe, Kenichi
    Hagio, Kanako
    Baba, Motoi
    Ikarashi, Mayuko
    Sato, Masako
    Tomioka, Nobumoto
    Takahashi, Masato
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
12345